Kyverna Therapeutics, Inc.
KYTX
$1.83
-$0.005-0.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 145.38% | 169.03% | -- | -- | -- |
| Gross Profit | -145.38% | -171.17% | -- | -- | -- |
| SG&A Expenses | 137.99% | 129.84% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.78% | 160.17% | -- | -- | -- |
| Operating Income | -143.78% | -161.77% | -- | -- | -- |
| Income Before Tax | -123.57% | -146.74% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -123.57% | -146.74% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -123.57% | -146.74% | -- | -- | -- |
| EBIT | -143.78% | -161.77% | -- | -- | -- |
| EBITDA | -191.88% | -230.86% | -- | -- | -- |
| EPS Basic | 95.63% | 58.72% | -- | -- | -- |
| Normalized Basic EPS | 95.65% | 58.85% | -- | -- | -- |
| EPS Diluted | 95.63% | 58.72% | -- | -- | -- |
| Normalized Diluted EPS | 95.65% | 58.85% | -- | -- | -- |
| Average Basic Shares Outstanding | 5,103.62% | 4,034.61% | -- | -- | -- |
| Average Diluted Shares Outstanding | 5,103.62% | 4,034.61% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |